TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Healios KK ( (JP:4593) ) has provided an update.
Healios K.K. has entered into a letter of intent with Cell Resources Co., Ltd. to collaborate on the production of cell culture supernatant, a raw material for regenerative medical products. This alliance aims to establish a manufacturing facility and supply chain, enhancing Healios’s capacity to meet the demands of its joint research agreement with AND medical. The agreement signifies a strategic move to bolster Healios’s operational capabilities in regenerative medicine, potentially impacting its market positioning and expanding its reach in providing innovative treatments.
More about Healios KK
Healios K.K. is Japan’s leading clinical stage biotechnology company specializing in regenerative medicine using stem cells. The company is pioneering new therapies for diseases with limited treatment options and is developing products like MultiStem for ischemic stroke, ARDS, and trauma, as well as iPSC-based treatments for solid tumors.
YTD Price Performance: 13.56%
Average Trading Volume: 818,622
Technical Sentiment Consensus Rating: Hold
Current Market Cap: Yen18.12B
For a thorough assessment of 4593 stock, go to TipRanks’ Stock Analysis page.